X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

PCI and Experic Join Forces in Drug Supply Chain Ecosystem Partnership

Content Team by Content Team
3rd June 2020
in Press Statements
PCI and Experic Join Forces in Drug Supply Chain Ecosystem Partnership

PCI Pharma Services (PCI), a pharmaceutical and biopharmaceutical global outsourcing solutions provider, and Experic, a contract manufacturing organization (CMO) and pharmaceutical supply service company, are joining forces with a strategic, synergistic partnership involving clinical and commercial manufacturing, packaging and supply chain services.

The agreement will give Experic access to PCI’s clinical and commercial supply chain capabilities and strong presence in Europe. In turn, Experic will provide PCI access to advanced powder-filling equipment and capabilities including low dose filling for inhalation and other delivery modalities. This partnership will enhance the growth and success of both organizations.

“We’re extremely pleased to be working with Experic, whose expertise in dry powder inhalation and other scalable manufacturing solutions will mean added value for our clients and our future as a company,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Sharing capabilities and collaborating on services will allow our respective differentiators to complement one another, strengthening both companies, and allowing us to provide patients new and better treatments within a complex drug supply chain ecosystem.”

Jeff McMullen, chief executive officer, Experic, said, “This exciting partnership with PCI, a leading global outsourcing solutions provider to pharma and biopharma companies, facilitates a rapid expansion of the services we offer to clients. It’s a partnership that makes sense for both organizations—providing access to solutions that help each company expand its portfolio of offerings to clients.”

Under the reciprocal agreement, Experic will have access to PCI’s integrated full services in the EU, including the PCI European quality control team, providing their clients access to manufacturing, packaging, storage and delivery services that facilitate clinical trials in the region.

For PCI, Experic brings state-of-the-art manufacturing technologies and filling equipment for micro-dosing through its partnership with Germany-based Harro Höfliger. Experic’s low dose powder filling capabilities will also enable the efficient transition of products from clinical to commercial-scale manufacturing.

Previous Post

AbCellera's Rapid Pandemic Response Platform Contributes to the World's First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

Next Post

AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Drug Development

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

4th March 2025
Next Post
Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In